Business Context and Reporting Period
This Form 8-K is filed by Cognition Therapeutics, Inc. (CGTX), a Delaware corporation and emerging growth company, on August 26, 2025. The report addresses a specific corporate event regarding the company's listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock price rather than financial performance.
Material Changes
The primary material change reported is the resolution of a listing deficiency:
- Prior Status: On September 12, 2024, the Company received a deficiency letter from Nasdaq because its common stock closed below the $1.00 minimum bid price requirement for 30 consecutive trading days.
- Current Status: As of August 25, 2025, the Company's stock closed above $1.00 per share for more than ten consecutive trading days.
- Outcome: On August 26, 2025, Nasdaq advised the Company that it has regained compliance with the Minimum Bid Price Requirement (Listing Rule 5450(a)(1)).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The primary risk addressed was the potential delisting due to low stock price, which has been mitigated by the recent price recovery. No other contingencies or unusual items are disclosed in this document.
Investor Verification Checklist
- Verify the current trading price of CGTX to ensure it remains above the $1.00 threshold to maintain Nasdaq compliance.
- Confirm the date of the Nasdaq compliance letter (August 26, 2025) against public exchange announcements.
- Review the company's most recent 10-Q or 10-K for financial metrics, as this 8-K does not contain financial data.